SRZN (Surrozen) Retained Earnings : $-285.26 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Surrozen's retained earnings for the quarter that ended in Dec. 2024 was $-285.26 Mil.

Surrozen's quarterly retained earnings declined from Jun. 2024 ($-255.79 Mil) to Sep. 2024 ($-257.22 Mil) and declined from Sep. 2024 ($-257.22 Mil) to Dec. 2024 ($-285.26 Mil).

Surrozen's annual retained earnings declined from Dec. 2022 ($-178.65 Mil) to Dec. 2023 ($-221.70 Mil) and declined from Dec. 2023 ($-221.70 Mil) to Dec. 2024 ($-285.26 Mil).

Surrozen Retained Earnings Historical Data

The historical data trend for Surrozen's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Retained Earnings Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

-88.00

-142.65

-178.65

-221.70

-285.26

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial													-221.70	-230.53	-255.79	-257.22	-285.26

Surrozen Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Surrozen (NAS:SRZN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Surrozen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Executives

Charles O Williams	officer: Chief Financial Officer	C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Tim Kutzkey	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Anna Berkenblit	director	830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md	director, 10 percent owner	1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai	director	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh	officer: Chief Scientific Officer	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory	other: Former VP Business Development	C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove	officer: Chief Medical Officer	1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel	other: Former Director	4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse	director	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158